Anticompulsive Activity of a New Pyrazolo[C]Pyridine Derivative GIZh-72 under Conditions of Unpredictable Chronic Mild Stress
- Autores: Kudryashov N.V.1, Kalinina T.S.1, Zhmurenko L.A.1, Voronina T.A.1
- 
							Afiliações: 
							- V. V. Zakusov Research Institute of Pharmacology
 
- Edição: Volume 161, Nº 3 (2016)
- Páginas: 377-380
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/237436
- DOI: https://doi.org/10.1007/s10517-016-3418-y
- ID: 237436
Citar
Resumo
Anticompulsive activity of a novel compound GIZh-72 (4,6-dimethyl-2-(4-chlorphenyl)-2,3-dihydro-1H-pyrazolo[4,3-C]Pyridine-3-on, chloral hydrate) in a dose of 20 mg/kg (single, subchronic, and chronic administration) in comparison with fluvoxamine (25 mg/kg) was studied in the marble burying test in the model of unpredictable chronic mild stress on BALB/c mice. GIZh-72 produced an anticompulsive effect that increased with increasing treatment duration under stress conditions in contrast to fluvoxamine that induced inversion of this effect after long-term administration. Neuroleptic activity of GIZh-72 in doses of 20 and 40 mg/kg was studied on the model of apomorphine-induced climbing in C57Bl/6 mice. In contrast to haloperidol (0.5 mg/kg), GIZh-72 exhibited no neuroleptic properties. Our results indicate that GIZh-72 holds much promise for pharmacotherapy of obsessive-compulsive disorder.
Sobre autores
N. Kudryashov
V. V. Zakusov Research Institute of Pharmacology
							Autor responsável pela correspondência
							Email: kunvi@mail.ru
				                					                																			                												                	Rússia, 							Moscow						
T. Kalinina
V. V. Zakusov Research Institute of Pharmacology
														Email: kunvi@mail.ru
				                					                																			                												                	Rússia, 							Moscow						
L. Zhmurenko
V. V. Zakusov Research Institute of Pharmacology
														Email: kunvi@mail.ru
				                					                																			                												                	Rússia, 							Moscow						
T. Voronina
V. V. Zakusov Research Institute of Pharmacology
														Email: kunvi@mail.ru
				                					                																			                												                	Rússia, 							Moscow						
Arquivos suplementares
 
				
			 
						 
						 
						 
						 
					 
				 
  
  
  
  
  Enviar artigo por via de e-mail
			Enviar artigo por via de e-mail  Acesso aberto
		                                Acesso aberto Acesso está concedido
						Acesso está concedido Somente assinantes
		                                		                                        Somente assinantes
		                                					